Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects

BACKGROUND AND OBJECTIVES: Fidaxomicin treatment of Clostridium difficile infection is known to produce minimal systemic exposure, as the antibacterial (antibiotic) remains primarily in the gut. In this randomized, double-blind, placebo-controlled study, the safety, tolerability, and pharmacokinetic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Drug Investig
Egile Nagusiak: Oshima, Hiroyuki, Yamazaki, Takao, Benner, Lauren, Miki, Takashi, Michon, Ingrid, Wojtkowski, Tomasz, Kaibara, Atsunori, Mujais, Salim
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2015
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4449367/
https://ncbi.nlm.nih.gov/pubmed/25972286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-015-0291-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak